BrainAurora Overhauls Board With New Non-Executive Directors From Finance and Pharma

BrainAurora Medical Technology Limited ( (HK:6681) ) has shared an announcement.

BrainAurora Medical Technology Limited announced the resignation of non-executive directors Li Mingqiu and Li Sirui, effective April 15, 2026, citing other work commitments and personal time arrangements, with both confirming no disagreements with the board or issues requiring shareholder attention. The company has appointed Yang Fan, a seasoned corporate finance executive, and Wang Jingbo, a veteran in pharmaceutical sales and marketing, as new non-executive directors under standard appointment terms, a move that is expected to strengthen the board’s financial oversight and commercial capabilities in the healthcare sector.

Yang Fan brings over two decades of experience in corporate finance and leadership roles at financial leasing and investment firms, while maintaining an existing non-executive directorship at Immunotech Biopharm Ltd in Hong Kong. Wang Jingbo contributes more than 20 years of sales management experience focused on pharmaceutical marketing in China, and together their appointments signal BrainAurora’s effort to reinforce governance and strategic alignment with both capital markets and the pharmaceutical commercial landscape.

More about BrainAurora Medical Technology Limited

BrainAurora Medical Technology Limited is a Cayman Islands–incorporated company listed in Hong Kong, operating in the medical technology sector. The group focuses on healthcare-related products and services, positioning itself within the broader pharmaceutical and medtech ecosystem, with ties to both financial and pharmaceutical industry expertise through its board composition.

Average Trading Volume: 22,958,184

Technical Sentiment Signal: Strong Sell

Current Market Cap: HK$5.42B

Find detailed analytics on 6681 stock on TipRanks’ Stock Analysis page.